Are You Eligible for Targeted Therapy?

With a simple blood test, Myriad can let you and your physician better understand if you are a candidate for the cancer treatment, Lynparza® (olaparib). 1,2

  1. Intended Use: BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.

    Results of the test are used as an aid in identifying breast and ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants, who are or may become eligible for treatment with Lynparza® (olaparib). Detection of deleterious or suspected deleterious germline BRCA variants by the BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at 320 Wakara Way, Salt Lake City, UT 84108.
  2. For more detailed information about Lynparza and its safety and efficacy please go to
  3. Robson et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med (2017).377:523-5332.
Lynparza is a registered trademark of the AstraZeneca group of companies. Zejula is a registered trademark of Tesaro, Inc.

Myriad, the Myriad logo, BRACAnalysis CDx the BRACAnalysis CDx logo, Myriad Promise and the Myriad Promise logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions. ©2018, Myriad Genetics, Inc